Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis.
Adding localized cancer treatments to immunotherapy showed signs of extending survival in advanced lung cancer, though more rigorous studies are needed.
This systematic review and meta-analysis examined Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis. Local ablative treatment during continued immunotherapy was associated with improved progression-free survival and overall survival, but the evidence was predominantly observational and low certainty.
What the study was
- Study design
- Systematic review and meta-analysis
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Oncoimmunology
Why it surfaced
Abstract-backed systematic review and meta-analysis relevant to Novel therapeutics: immunotherapy, CAR-T, targeted therapy; scored conservatively because full text was not assessed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.